Drug intelligence / Profile preview

ImmunAg

Development stage: Unknown
Lead developer: ImmunAg
Modality: Small Molecules
Administration: Oral

Overview

ImmunAg is a non-cannabis derived cannabidiol (CBD) oil product extracted from the patented Kriya Hops (*Humulus*) plant. Developed by the Goa-based company ImmunAg LLP, it contains a combination of CBD, β-caryophyllene, and α-humulene. Unlike traditional CBD products sourced from hemp or marijuana, ImmunAg utilizes hops as its botanical source, which allows it to be marketed as a food ingredient under Food Safety and Standards Authority of India (FSSAI) certification. The product is designed to interact with the endocannabinoid system, particularly the CB2 receptors, to provide anti-inflammatory and immune-modulating benefits without the psychoactive effects associated with THC.

Brand names: ImmunAg
Other names: Kriya Hops CBD oil

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on ImmunAg.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunAg.

Explore the full profile